All Publications

  1. Rice BA, Ver Hoeve ES, DeLuca AN, Esserman LJ, Rugo HS, Melisko ME. Registry study to assess hair loss prevention with the Penguin Cold Cap in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat. 2017 Sep 18. View in PubMed
  2. Esserman LJ. The WISDOM Study: breaking the deadlock in the breast cancer screening debate. NPJ Breast Cancer. 2017; 3:34. View in PubMed
  3. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Breast Cancer Res. 2017 Sep 11; 19(1):107. View in PubMed
  4. Wolf DM, Yau C, Sanil A, Glas A, Petricoin E, Wulfkuhle J, Severson TM, Linn S, Brown-Swigart L, Hirst G, Buxton M, DeMichele A, Hylton N, Symmans F, Yee D, Paoloni M, Esserman L, Berry D, Rugo H, Olopade O, van 't Veer L. DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial. NPJ Breast Cancer. 2017; 3:31. View in PubMed
  5. van 't Veer LJ, Yau C, Yu NY, Benz CC, Nordenskjöld B, Fornander T, Stål O, Esserman LJ, Lindström LS. Tamoxifen therapy benefit for patients with 70-gene signature high and low risk. Breast Cancer Res Treat. 2017 Aug 04. View in PubMed
  6. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):161. View in PubMed
  7. Fowble B, Jairam AK, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Park C, Lazar A. Indications for Postmastectomy Radiation After Neoadjuvant Chemotherapy in ypN0 and ypN1-3 Axillary Node-Positive Women. Clin Breast Cancer. 2017 Aug 01. View in PubMed
  8. Esserman LJ, Yau C, Thompson CK, van 't Veer LJ, Borowsky AD, Hoadley KA, Tobin NP, Nordenskjöld B, Fornander T, Stål O, Benz CC, Lindström LS. Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades. JAMA Oncol. 2017 Jun 29. View in PubMed
  9. Vidula N, Yau C, Li J, Esserman LJ, Rugo HS. Receptor activator of nuclear factor kappa B (RANK) expression in primary breast cancer correlates with recurrence-free survival and development of bone metastases in I-SPY1 (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):129-138. View in PubMed
  10. Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2017 Aug; 165(1):181-191. View in PubMed
  11. Peled AW, Sears M, Wang F, Foster RD, Alvarado M, Wong J, Ewing CA, Sbitany H, Esserman LJ, Fowble B. Complications After Total Skin-Sparing Mastectomy and Expander-Implant Reconstruction: Effects of Radiation Therapy on the Stages of Reconstruction. Ann Plast Surg. 2017 Jun 01. View in PubMed
  12. Chien AJ, Chambers J, Mcauley F, Kaplan T, Letourneau J, Hwang J, Kim MO, Melisko ME, Rugo HS, Esserman LJ, Rosen MP. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy. Breast Cancer Res Treat. 2017 Aug; 165(1):151-159. View in PubMed
  13. Melisko ME, Goldman ME, Hwang J, De Luca A, Fang S, Esserman LJ, Chien AJ, Park JW, Rugo HS. Vaginal Testosterone Cream vs Estradiol Vaginal Ring for Vaginal Dryness or Decreased Libido in Women Receiving Aromatase Inhibitors for Early-Stage Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2017 Mar 01; 3(3):313-319. View in PubMed
  14. Rugo HS, Klein P, Melin SA, Hurvitz SA, Melisko ME, Moore A, Park G, Mitchel J, Bågeman E, D'Agostino RB, Ver Hoeve ES, Esserman L, Cigler T. Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer. JAMA. 2017 02 14; 317(6):606-614. View in PubMed
  15. Hosseini A, Khoury AL, Esserman LJ. Precision surgery and avoiding over-treatment. Eur J Surg Oncol. 2017 May; 43(5):938-943. View in PubMed
  16. Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, Ziv E, Van't Veer LJ, Esserman LJ, Tice JA. Breast Cancer Screening in the Precision Medicine Era: Risk-Based Screening in a Population-Based Trial. J Natl Cancer Inst. 2017 01; 109(5). View in PubMed
  17. Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, Ma CX, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). J Clin Oncol. 2017 Apr 01; 35(10):1061-1069. View in PubMed
  18. Jones EF, Ray KM, Li W, Seo Y, Franc BL, Chien AJ, Esserman LJ, Pampaloni MH, Joe BN, Hylton NM. Dedicated Breast Positron Emission Tomography for the Evaluation of Early Response to Neoadjuvant Chemotherapy in Breast Cancer. Clin Breast Cancer. 2017 Jun; 17(3):e155-e159. View in PubMed
  19. Bolan PJ, Kim E, Herman BA, Newstead GM, Rosen MA, Schnall MD, Pisano ED, Weatherall PT, Morris EA, Lehman CD, Garwood M, Nelson MT, Yee D, Polin SM, Esserman LJ, Gatsonis CA, Metzger GJ, Newitt DC, Partridge SC, Hylton NM. MR spectroscopy of breast cancer for assessing early treatment response: Results from the ACRIN 6657 MRS trial. J Magn Reson Imaging. 2017 Jul; 46(1):290-302. View in PubMed
  20. Li W, Arasu V, Newitt DC, Jones EF, Wilmes L, Gibbs J, Kornak J, Joe BN, Esserman LJ, Hylton NM. Effect of MR Imaging Contrast Thresholds on Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes: A Subgroup Analysis of the ACRIN 6657/I-SPY 1 TRIAL. Tomography. 2016 Dec; 2(4):378-387. View in PubMed
  21. Wang F, Chin R, Piper M, Esserman L, Sbitany H. Do Prolonged Prophylactic Antibiotics Reduce the Incidence of Surgical-Site Infections in Immediate Prosthetic Breast Reconstruction? Plast Reconstr Surg. 2016 Dec; 138(6):1141-1149. View in PubMed
  22. Amara D, Wolf DM, van 't Veer L, Esserman L, Campbell M, Yau C. Co-expression modules identified from published immune signatures reveal five distinct immune subtypes in breast cancer. Breast Cancer Res Treat. 2017 Jan; 161(1):41-50. View in PubMed
  23. Campbell MJ, Baehner F, O'Meara T, Ojukwu E, Han B, Mukhtar R, Tandon V, Endicott M, Zhu Z, Wong J, Krings G, Au A, Gray JW, Esserman L. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast. Breast Cancer Res Treat. 2016 Oct 26. View in PubMed
  24. Berry D, Esserman L. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 10 20; 375(16):1592-3. View in PubMed
  25. Trusheim MR, Shrier AA, Antonijevic Z, Beckman RA, Campbell RK, Chen C, Flaherty KT, Loewy J, Lacombe D, Madhavan S, Selker HP, Esserman LJ. PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms. Clin Pharmacol Ther. 2016 Dec; 100(6):713-729. View in PubMed
  26. Esserman L. The I-SPY approach to drug development. Clin Adv Hematol Oncol. 2016 Oct; 14(10):782-784. View in PubMed
  27. Esserman LJ, Thompson IM. Laura Esserman and Ian Thompson Discuss Strategies for Screening and Treatment of Early-Stage Cancers, and How Clinicians Can Learn From Each Other's Experiences. Oncology (Williston Park). 2016 09 15; 30(9):770, 785-6. View in PubMed
  28. Mukhtar RA, Piper ML, Freise C, Van't Veer LJ, Baehner FL, Esserman LJ. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer. Am J Transplant. 2017 Jan; 17(1):292-295. View in PubMed
  29. Rugo HS, Olopade OI, DeMichele A, Yau C, van 't Veer LJ, Buxton MB, Hogarth M, Hylton NM, Paoloni M, Perlmutter J, Symmans WF, Yee D, Chien AJ, Wallace AM, Kaplan HG, Boughey JC, Haddad TC, Albain KS, Liu MC, Isaacs C, Khan QJ, Lang JE, Viscusi RK, Pusztai L, Moulder SL, Chui SY, Kemmer KA, Elias AD, Edmiston KK, Euhus DM, Haley BB, Nanda R, Northfelt DW, Tripathy D, Wood WC, Ewing C, Schwab R, Lyandres J, Davis SE, Hirst GL, Sanil A, Berry DA, Esserman LJ. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34. View in PubMed
  30. Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):11-22. View in PubMed
  31. Esserman L. When Less Is Better, but Physicians Are Afraid Not to Intervene. JAMA Intern Med. 2016 Jul 01; 176(7):888-9. View in PubMed
  32. Katchman BA, Barderas R, Alam R, Chowell D, Field MS, Esserman LJ, Wallstrom G, LaBaer J, Cramer DW, Hollingsworth MA, Anderson KS. Proteomic mapping of p53 immunogenicity in pancreatic, ovarian, and breast cancers. Proteomics Clin Appl. 2016 Jul; 10(7):720-31. View in PubMed
  33. Piper ML, Esserman LJ, Sbitany H, Peled AW. Outcomes Following Oncoplastic Reduction Mammoplasty: A Systematic Review. Ann Plast Surg. 2016 May; 76 Suppl 3:S222-6. View in PubMed
  34. Shieh Y, Eklund M, Sawaya GF, Black WC, Kramer BS, Esserman LJ. Population-based screening for cancer: hope and hype. Nat Rev Clin Oncol. 2016 Sep; 13(9):550-65. View in PubMed
  35. Borowsky A, Esserman L. When the Gold Standard Loses Its Luster, Perhaps It Is Time to Change Nomenclature. Ann Intern Med. 2016 May 17; 164(10):694-5. View in PubMed
  36. Esserman L, Yau C. Treatment and Long-Term Risks for Patients With a Diagnosis of Ductal Carcinoma In Situ-Reply. JAMA Oncol. 2016 Mar; 2(3):395-6. View in PubMed
  37. Lo WC, Li W, Jones EF, Newitt DC, Kornak J, Wilmes LJ, Esserman LJ, Hylton NM. Effect of Imaging Parameter Thresholds on MRI Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer Subtypes. PLoS One. 2016; 11(2):e0142047. View in PubMed
  38. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser MM, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. View in PubMed
  39. Winters ZE, Horsnell J, Schmid P, Jones JL, Shaaban A, Maxwell AJ, Williams N, Esserman L, Jatoi I, Brunt AM. Time for a randomised clinical trial evaluating breast conserving surgery compared to mastectomy in ipsilateral mutlifocal breast cancer (MFBC)? Breast. 2016 Apr; 26:149-50. View in PubMed
  40. Shieh Y, Eklund M, Esserman L. Detection of ductal carcinoma in situ and subsequent interval cancers. BMJ. 2016 Feb 01; 352:i551. View in PubMed
  41. Merrill AL, Esserman L, Morrow M. CLINICAL DECISIONS. Ductal Carcinoma In Situ. N Engl J Med. 2016 Jan 28; 374(4):390-2. View in PubMed
  42. DeMichele A, Yee D, Paoloni M, Berry D, Esserman LJ. Neoadjuvant as Future for Drug Development in Breast Cancer--Response. Clin Cancer Res. 2016 Jan 01; 22(1):269. View in PubMed
  43. Esserman L, Gallant E, Alvarado M. Less Is More: The Evolving Surgical Approach to Breast Cancer. Am Soc Clin Oncol Educ Book. 2016; 35:e5-e10. View in PubMed
  44. Sbitany H, Wang F, Peled AW, Alvarado M, Ewing CA, Esserman LJ, Foster RD. Tissue Expander Reconstruction After Total Skin-Sparing Mastectomy: Defining the Effects of Coverage Technique on Nipple/Areola Preservation. Ann Plast Surg. 2016 Jan; 77(1):17-24. View in PubMed
  45. Wang F, Peled AW, Chin R, Fowble B, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H. The Impact of Radiation Therapy, Lymph Node Dissection, and Hormonal Therapy on Outcomes of Tissue Expander-Implant Exchange in Prosthetic Breast Reconstruction. Plast Reconstr Surg. 2016 Jan; 137(1):1-9. View in PubMed
  46. Johnson J, Esserman L, Ewing C, Alvarado M, Park C, Fowble B. Sentinel Lymph Node Mapping in Post-Mastectomy Chest Wall Recurrences: Influence on Radiation Treatment Fields and Outcome. Ann Surg Oncol. 2016 Mar; 23(3):715-21. View in PubMed
  47. Hylton NM, Gatsonis CA, Rosen MA, Lehman CD, Newitt DC, Partridge SC, Bernreuter WK, Pisano ED, Morris EA, Weatherall PT, Polin SM, Newstead GM, Marques HS, Esserman LJ, Schnall MD. Neoadjuvant Chemotherapy for Breast Cancer: Functional Tumor Volume by MR Imaging Predicts Recurrence-free Survival-Results from the ACRIN 6657/CALGB 150007 I-SPY 1 TRIAL. Radiology. 2016 Apr; 279(1):44-55. View in PubMed
  48. Esserman L, Yau C. Rethinking the Standard for Ductal Carcinoma In Situ Treatment. JAMA Oncol. 2015 Oct; 1(7):881-3. View in PubMed
  49. Wang F, Amara D, Peled AW, Sbitany H, Foster RD, Ewing CA, Alvarado M, Esserman LJ. Negative Genetic Testing Does Not Deter Contralateral Prophylactic Mastectomy in Younger Patients with Greater Family Histories of Breast Cancer. Ann Surg Oncol. 2015 Oct; 22(10):3338-45. View in PubMed
  50. Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. 2015 Aug; 153(1):173-81. View in PubMed
  51. Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Mod Pathol. 2015 Sep; 28(9):1185-201. View in PubMed
  52. Price ER, Wong J, Mukhtar R, Hylton N, Esserman LJ. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer. World J Clin Cases. 2015 Jul 16; 3(7):607-13. View in PubMed
  53. Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M. In Regard to Hepel and Wazer. Int J Radiat Oncol Biol Phys. 2015 Aug 01; 92(5):953-954. View in PubMed
  54. Peled AW, Wang F, Foster RD, Alvarado M, Ewing CA, Sbitany H, Esserman LJ. Expanding the Indications for Total Skin-Sparing Mastectomy: Is It Safe for Patients with Locally Advanced Disease? Ann Surg Oncol. 2016 Jan; 23(1):87-91. View in PubMed
  55. Mukhtar RA, Wong JM, Esserman LJ. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care. J Natl Compr Canc Netw. 2015 Jun; 13(6):737-43. View in PubMed
  56. Magbanua MJ, Wolf DM, Yau C, Davis SE, Crothers J, Au A, Haqq CM, Livasy C, Rugo HS, Esserman L, Park JW, van 't Veer LJ. Serial expression analysis of breast tumors during neoadjuvant chemotherapy reveals changes in cell cycle and immune pathways associated with recurrence and response. Breast Cancer Res. 2015 May 29; 17:73. View in PubMed
  57. Amara D, Peled AW, Wang F, Ewing CA, Alvarado M, Esserman LJ. Tumor Involvement of the Nipple in Total Skin-Sparing Mastectomy: Strategies for Management. Ann Surg Oncol. 2015 Nov; 22(12):3803-8. View in PubMed
  58. Belkora J, Volz S, Loth M, Teng A, Zarin-Pass M, Moore D, Esserman L. Coaching patients in the use of decision and communication aids: RE-AIM evaluation of a patient support program. BMC Health Serv Res. 2015 May 28; 15:209. View in PubMed
  59. Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015 Jul; 26(7):1280-91. View in PubMed
  60. Piper M, Peled AW, Sbitany H, Foster RD, Esserman LJ, Price ER. Comparison of Mammographic Findings Following Oncoplastic Mammoplasty and Lumpectomy Without Reconstruction. Ann Surg Oncol. 2016 Jan; 23(1):65-71. View in PubMed
  61. Raghavan S, Peled AW, Hansen SL, Esserman LJ, Sbitany H. Approaches to microvascular breast reconstruction after total skin-sparing mastectomy: a comparison of techniques. Ann Plast Surg. 2015 May; 74 Suppl 1:S46-51. View in PubMed
  62. Fowble B, Park C, Wang F, Peled A, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H, Hanlon A. Rates of Reconstruction Failure in Patients Undergoing Immediate Reconstruction With Tissue Expanders and/or Implants and Postmastectomy Radiation Therapy. Int J Radiat Oncol Biol Phys. 2015 Jul 01; 92(3):634-41. View in PubMed
  63. Vaidya JS, Bulsara M, Wenz F, Joseph D, Saunders C, Massarut S, Flyger H, Eiermann W, Alvarado M, Esserman L, Falzon M, Brew-Graves C, Potyka I, Tobias JS, Baum M. Pride, Prejudice, or Science: Attitudes Towards the Results of the TARGIT-A Trial of Targeted Intraoperative Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys. 2015 Jul 01; 92(3):491-7. View in PubMed
  64. Wang F, Alvarado M, Ewing C, Esserman L, Foster R, Sbitany H. The impact of breast mass on outcomes of total skin-sparing mastectomy and immediate tissue expander-based breast reconstruction. Plast Reconstr Surg. 2015 Mar; 135(3):672-9. View in PubMed
  65. DeMichele A, Yee D, Berry DA, Albain KS, Benz CC, Boughey J, Buxton M, Chia SK, Chien AJ, Chui SY, Clark A, Edmiston K, Elias AD, Forero-Torres A, Haddad TC, Haley B, Haluska P, Hylton NM, Isaacs C, Kaplan H, Korde L, Leyland-Jones B, Liu MC, Melisko M, Minton SE, Moulder SL, Nanda R, Olopade OI, Paoloni M, Park JW, Parker BA, Perlmutter J, Petricoin EF, Rugo H, Symmans F, Tripathy D, van't Veer LJ, Viscusi RK, Wallace A, Wolf D, Yau C, Esserman LJ. The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer. Clin Cancer Res. 2015 Jul 01; 21(13):2911-5. View in PubMed
  66. Warner JL, Maddux SE, Hughes KS, Krauss JC, Yu PP, Shulman LN, Mayer DK, Hogarth M, Shafarman M, Stover Fiscalini A, Esserman L, Alschuler L, Koromia GA, Gonzaga Z, Ambinder EP. Development, implementation, and initial evaluation of a foundational open interoperability standard for oncology treatment planning and summarization. J Am Med Inform Assoc. 2015 May; 22(3):577-86. View in PubMed
  67. Langford DJ, Schmidt B, Levine JD, Abrams G, Elboim C, Esserman L, Hamolsky D, Mastick J, Paul SM, Cooper B, Kober K, Dodd M, Dunn L, Aouizerat B, Miaskowski C. Preoperative Breast Pain Predicts Persistent Breast Pain and Disability After Breast Cancer Surgery. J Pain Symptom Manage. 2015 Jun; 49(6):981-94. View in PubMed
  68. Marks JR, Anderson KS, Engstrom P, Godwin AK, Esserman LJ, Longton G, Iversen ES, Mathew A, Patriotis C, Pepe MS. Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. Cancer Epidemiol Biomarkers Prev. 2015 Feb; 24(2):435-41. View in PubMed
  69. Wheelock AE, Bock MA, Martin EL, Hwang J, Ernest ML, Rugo HS, Esserman LJ, Melisko ME. SIS.NET: a randomized controlled trial evaluating a web-based system for symptom management after treatment of breast cancer. Cancer. 2015 Mar 15; 121(6):893-9. View in PubMed
  70. Lang JE, Scott JH, Wolf DM, Novak P, Punj V, Magbanua MJ, Zhu W, Mineyev N, Haqq CM, Crothers JR, Esserman LJ, Tripathy D, van 't Veer L, Park JW. Expression profiling of circulating tumor cells in metastatic breast cancer. Breast Cancer Res Treat. 2015 Jan; 149(1):121-31. View in PubMed
  71. Sbitany H, Wang F, Peled AW, Lentz R, Alvarado M, Ewing CA, Esserman LJ, Fowble B, Foster RD. Immediate implant-based breast reconstruction following total skin-sparing mastectomy: defining the risk of preoperative and postoperative radiation therapy for surgical outcomes. Plast Reconstr Surg. 2014 Sep; 134(3):396-404. View in PubMed
  72. Eklund M, O'Donoghue C, Esserman LJ. Aggregate cost of mammography screening in the United States. Ann Intern Med. 2014 Aug 19; 161(4):305. View in PubMed
  73. Degnim AC, Hoskin TL, Brahmbhatt RD, Warren-Peled A, Loprinzi M, Pavey ES, Boughey JC, Hieken TJ, Jacobson S, Lemaine V, Jakub JW, Irwin C, Foster RD, Sbitany H, Saint-Cyr M, Duralde E, Ramaker S, Chin R, Sieg M, Wildeman M, Scow JS, Patel R, Ballman K, Baddour LM, Esserman LJ. Randomized trial of drain antisepsis after mastectomy and immediate prosthetic breast reconstruction. Ann Surg Oncol. 2014 Oct; 21(10):3240-8. View in PubMed
  74. Peled AW, Foster RD, Ligh C, Esserman LJ, Fowble B, Sbitany H. Impact of total skin-sparing mastectomy incision type on reconstructive complications following radiation therapy. Plast Reconstr Surg. 2014 Aug; 134(2):169-75. View in PubMed
  75. Esserman L, Hayes M, Alvarado M. Haste makes waste, but lack of urgency is opportunity lost. Breast Cancer Res Treat. 2014 Aug; 147(1):223-4. View in PubMed
  76. Esserman L, O'Kane ME. Moving beyond the breast cancer screening debate. J Womens Health (Larchmt). 2014 Aug; 23(8):629-30. View in PubMed
  77. Wang F, Peled AW, Garwood E, Fiscalini AS, Sbitany H, Foster RD, Alvarado M, Ewing C, Hwang ES, Esserman LJ. Total skin-sparing mastectomy and immediate breast reconstruction: an evolution of technique and assessment of outcomes. Ann Surg Oncol. 2014 Oct; 21(10):3223-30. View in PubMed
  78. Sbitany H, Wang F, Saeed L, Alvarado M, Ewing CA, Esserman LJ, Foster RD. Immediate implant-based breast reconstruction following total skin-sparing mastectomy in women with a history of augmentation mammaplasty: assessing the safety profile. Plast Reconstr Surg. 2014 Jul; 134(1):1-9. View in PubMed
  79. Elias SG, Adams A, Wisner DJ, Esserman LJ, van't Veer LJ, Mali WP, Gilhuijs KG, Hylton NM. Imaging features of HER2 overexpression in breast cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Aug; 23(8):1464-83. View in PubMed
  80. Peled AW, Sbitany H, Foster RD, Esserman LJ. Oncoplastic mammoplasty as a strategy for reducing reconstructive complications associated with postmastectomy radiation therapy. Breast J. 2014 May-Jun; 20(3):302-7. View in PubMed
  81. Peled AW, Duralde E, Foster RD, Fiscalini AS, Esserman LJ, Hwang ES, Sbitany H. Patient-reported outcomes and satisfaction after total skin-sparing mastectomy and immediate expander-implant reconstruction. Ann Plast Surg. 2014 May; 72 Suppl 1:S48-52. View in PubMed
  82. Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014 May; 15(6):e234-42. View in PubMed
  83. Kerlikowske K, O'Kane ME, Esserman LJ. Fifty years of age-based screening: time for a new risk-based screening approach. Evid Based Med. 2014 Oct; 19(5):183. View in PubMed
  84. Cureton EL, Yau C, Alvarado MD, Krontiras H, Ollila DW, Ewing CA, Monnier S, Esserman LJ. Local recurrence rates are low in high-risk neoadjuvant breast cancer in the I-SPY 1 Trial (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2014 Sep; 21(9):2889-96. View in PubMed
  85. Esserman LJ, DeMichele A. Accelerated approval for pertuzumab in the neoadjuvant setting: winds of change? Clin Cancer Res. 2014 Jul 15; 20(14):3632-6. View in PubMed
  86. Clark AS, Chen J, Kapoor S, Friedman C, Mies C, Esserman L, DeMichele A. Pretreatment vitamin D level and response to neoadjuvant chemotherapy in women with breast cancer on the I-SPY trial (CALGB 150007/150015/ACRIN6657). Cancer Med. 2014 Jun; 3(3):693-701. View in PubMed
  87. Esserman L, Alvarado M. Setting a research agenda for ductal carcinoma in situ that meets the current need for change. Ann Intern Med. 2014 Apr 01; 160(7):511-2. View in PubMed
  88. Esserman LJ, Alvarado MD, Howe RJ, Mohan AJ, Harrison B, Park C, O'Donoghue C, Ozanne EM. Application of a decision analytic framework for adoption of clinical trial results: are the data regarding TARGIT-A IORT ready for prime time? Breast Cancer Res Treat. 2014 Apr; 144(2):371-8. View in PubMed
  89. Zarin-Pass M, Belkora J, Volz S, Esserman L. Making better doctors: a survey of premedical interns working as health coaches. J Cancer Educ. 2014 Mar; 29(1):167-74. View in PubMed
  90. Wang F, Peled A, Foster R, Wang E, Ewing C, Alvarado M, Esserman L, Sbitany H. Abstract 124: outcomes of total skin-sparing mastectomy and reconstruction in 924 breasts over 11 years. Plast Reconstr Surg. 2014 Mar; 133(3 Suppl):139. View in PubMed
  91. Jackson SA, Davis AA, Li J, Yi N, McCormick SR, Grant C, Fallen T, Crawford B, Loranger K, Litton J, Arun B, Vande Wydeven K, Sidani A, Farmer K, Sanders M, Hoskins K, Nussbaum R, Esserman L, Garber JE, Kaklamani VG. Characteristics of individuals with breast cancer rearrangements in BRCA1 and BRCA2. Cancer. 2014 May 15; 120(10):1557-64. View in PubMed
  92. O'Donoghue C, Eklund M, Ozanne EM, Esserman LJ. Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med. 2014 Feb 04; 160(3):145. View in PubMed
  93. Newitt DC, Aliu SO, Witcomb N, Sela G, Kornak J, Esserman L, Hylton NM. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. Transl Oncol. 2014 Feb; 7(1):94-100. View in PubMed
  94. Drukker CA, Schmidt MK, Rutgers EJ, Cardoso F, Kerlikowske K, Esserman LJ, van Leeuwen FE, Pijnappel RM, Slaets L, Bogaerts J, Van't Veer LJ. Mammographic screening detects low-risk tumor biology breast cancers. Breast Cancer Res Treat. 2014 Feb; 144(1):103-11. View in PubMed
  95. Ozanne EM, Howe R, Omer Z, Esserman LJ. Development of a personalized decision aid for breast cancer risk reduction and management. BMC Med Inform Decis Mak. 2014 Jan 14; 14:4. View in PubMed
  96. Esserman LJ, Thompson IM, Reid BJ. Changing the terminology of cancer--reply. JAMA. 2014 Jan 08; 311(2):203. View in PubMed
  97. Jafri NF, Newitt DC, Kornak J, Esserman LJ, Joe BN, Hylton NM. Optimized breast MRI functional tumor volume as a biomarker of recurrence-free survival following neoadjuvant chemotherapy. J Magn Reson Imaging. 2014 Aug; 40(2):476-82. View in PubMed
  98. Wells CJ, O'Donoghue C, Ojeda-Fournier H, Retallack HE, Esserman LJ. Evolving paradigm for imaging, diagnosis, and management of DCIS. J Am Coll Radiol. 2013 Dec; 10(12):918-23. View in PubMed
  99. Alvarado MD, Conolly J, Park C, Sakata T, Mohan AJ, Harrison BL, Hayes M, Esserman LJ, Ozanne EM. Patient preferences regarding intraoperative versus external beam radiotherapy following breast-conserving surgery. Breast Cancer Res Treat. 2014 Jan; 143(1):135-40. View in PubMed
  100. Vaidya JS, Wenz F, Bulsara M, Tobias JS, Joseph DJ, Keshtgar M, Flyger HL, Massarut S, Alvarado M, Saunders C, Eiermann W, Metaxas M, Sperk E, Sütterlin M, Brown D, Esserman L, Roncadin M, Thompson A, Dewar JA, Holtveg HM, Pigorsch S, Falzon M, Harris E, Matthews A, Brew-Graves C, Potyka I, Corica T, Williams NR, Baum M. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet. 2014 Feb 15; 383(9917):603-13. View in PubMed
  101. Eklund M, Esserman LJ. Screening: biology dictates the fate of young women with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):673-5. View in PubMed
  102. Campbell MJ, Wolf D, Mukhtar RA, Tandon V, Yau C, Au A, Baehner F, van't Veer L, Berry D, Esserman LJ. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context. PLoS One. 2013; 8(10):e79114. View in PubMed
  103. Omer ZB, Hwang ES, Esserman LJ, Howe R, Ozanne EM. Impact of ductal carcinoma in situ terminology on patient treatment preferences. JAMA Intern Med. 2013 Oct 28; 173(19):1830-1. View in PubMed
  104. Esserman LJ, Thompson IM, Reid B. Overdiagnosis and overtreatment in cancer: an opportunity for improvement. JAMA. 2013 Aug 28; 310(8):797-8. View in PubMed
  105. Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol. 2014 Jan; 21(1):37-41. View in PubMed
  106. Elson SL, Hiatt RA, Anton-Culver H, Howell LP, Naeim A, Parker BA, Van't Veer LJ, Hogarth M, Pierce JP, Duwors RJ, Hajopoulos K, Esserman LJ. The Athena Breast Health Network: developing a rapid learning system in breast cancer prevention, screening, treatment, and care. Breast Cancer Res Treat. 2013 Jul; 140(2):417-25. View in PubMed
  107. Alvarado MD, Mohan AJ, Esserman LJ, Park CC, Harrison BL, Howe RJ, Thorsen C, Ozanne EM. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer. Ann Surg Oncol. 2013 Sep; 20(9):2873-80. View in PubMed
  108. Vaughn CJ, Peled AW, Esserman LJ, Foster RD. Feasibility of Performing Total Skin-Sparing Mastectomy in Patients With Prior Circumareolar Mastopexy or Reduction Mammoplasty Incisions. Ann Plast Surg. 2013 Jun 19. View in PubMed
  109. Mukhtar RA, Yau C, Rosen M, Tandon VJ, Hylton N, Esserman LJ. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Ann Surg Oncol. 2013 Nov; 20(12):3823-30. View in PubMed
  110. Flowers CI, O'Donoghue C, Moore D, Goss A, Kim D, Kim JH, Elias SG, Fridland J, Esserman LJ. Reducing false-positive biopsies: a pilot study to reduce benign biopsy rates for BI-RADS 4A/B assessments through testing risk stratification and new thresholds for intervention. Breast Cancer Res Treat. 2013 Jun; 139(3):769-77. View in PubMed
  111. O'Donoghue C, Esserman L. Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement. Br J Cancer. 2013 Jun 11; 108(11):2200-1. View in PubMed
  112. Piper M, Peled AW, Foster RD, Moore DH, Esserman LJ. Total skin-sparing mastectomy: a systematic review of oncologic outcomes and postoperative complications. Ann Plast Surg. 2013 Apr; 70(4):435-7. View in PubMed
  113. DeMichele A, Berry DA, Zujewski J, Hunsberger S, Rubinstein L, Tomaszewski JE, Kelloff G, Perlmutter J, Buxton M, Lyandres J, Albain KS, Benz C, Chien AJ, Haluska P, Leyland-Jones B, Liu MC, Munster P, Olopade O, Park JW, Parker BA, Pusztai L, Tripathy D, Rugo H, Yee D, Esserman L. Developing safety criteria for introducing new agents into neoadjuvant trials. Clin Cancer Res. 2013 Jun 01; 19(11):2817-23. View in PubMed
  114. Peled AW, Esserman LJ. Reply: The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy. Plast Reconstr Surg. 2013 Feb; 131(2):279e. View in PubMed
  115. Yau C, Sninsky J, Kwok S, Wang A, Degnim A, Ingle JN, Gillett C, Tutt A, Waldman F, Moore D, Esserman L, Benz CC. An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk. Breast Cancer Res. 2013; 15(5):R103. View in PubMed
  116. Pass M, Volz S, Teng A, Esserman L, Belkora J. Physician behaviors surrounding the implementation of decision and communication AIDS in a breast cancer clinic: a qualitative analysis of staff intern perceptions. J Cancer Educ. 2012 Dec; 27(4):764-9. View in PubMed
  117. Esserman L, Ozanne E, van't Veer L. Will early detection for breast cancer ever work? Clin Chem. 2013 Jan; 59(1):190-3. View in PubMed
  118. Yee D, Haddad T, Albain K, Barker A, Benz C, Boughey J, Buxton M, Chien AJ, DeMichele A, Dilts D, Elias A, Haluska P, Hogarth M, Hu A, Hytlon N, Kaplan HG, Kelloff GG, Khan Q, Lang J, Leyland-Jones B, Liu M, Nanda R, Northfelt D, Olopade OI, Park J, Parker B, Parkinson D, Pearson-White S, Perlmutter J, Pusztai L, Symmans F, Rugo H, Tripathy D, Wallace A, Wholley D, Van't Veer L, Berry DA, Esserman L. Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol. 2012 Dec 20; 30(36):4584-6; author reply 4588-9. View in PubMed
  119. Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ, Vogel VG, Wolff AC, Somerfield MR, Davidson NE. Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Mar 01; 31(7):961-5. View in PubMed
  120. Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L, Liotta LA, Becker KF, Petricoin EF. Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping. Clin Cancer Res. 2012 Dec 01; 18(23):6426-35. View in PubMed
  121. Lips EH, Mukhtar RA, Yau C, de Ronde JJ, Livasy C, Carey LA, Loo CE, Vrancken-Peeters MJ, Sonke GS, Berry DA, Van't Veer LJ, Esserman LJ, Wesseling J, Rodenhuis S, Shelley Hwang E. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer. Breast Cancer Res Treat. 2012 Nov; 136(1):35-43. View in PubMed
  122. Petrillo LA, Wolf DM, Kapoun AM, Wang NJ, Barczak A, Xiao Y, Korkaya H, Baehner F, Lewicki J, Wicha M, Park JW, Spellman PT, Gray JW, van't Veer L, Esserman LJ. Xenografts faithfully recapitulate breast cancer-specific gene expression patterns of parent primary breast tumors. Breast Cancer Res Treat. 2012 Oct; 135(3):913-22. View in PubMed
  123. Peled AW, Foster RD, Esserman LJ, Park CC, Hwang ES, Fowble B. Increasing the time to expander-implant exchange after postmastectomy radiation therapy reduces expander-implant failure. Plast Reconstr Surg. 2012 Sep; 130(3):503-9. View in PubMed
  124. Autier P, Esserman LJ, Flowers CI, Houssami N. Breast cancer screening: the questions answered. Nat Rev Clin Oncol. 2012 10; 9(10):599-605. View in PubMed
  125. Bock M, Moore D, Hwang J, Shumay D, Lawson L, Hamolsky D, Esserman L, Rugo H, Chien AJ, Park J, Munster P, Melisko M. The impact of an electronic health questionnaire on symptom management and behavior reporting for breast cancer survivors. Breast Cancer Res Treat. 2012 Aug; 134(3):1327-35. View in PubMed
  126. Cohen E, Belkora J, Tyler J, Schreiner J, Deering MJ, Grama L, Duggan B, Illi J, Pederson J, Anand A, Teng A, McCreary E, Moore D, Tripathy D, Hogarth M, Lieberman M, Park J, Esserman L. Adoption, acceptability, and accuracy of an online clinical trial matching website for breast cancer. J Med Internet Res. 2012 Jul 11; 14(4):e97. View in PubMed
  127. Adisa CA, Eleweke N, Alfred AA, Campbell MJ, Sharma R, Nseyo O, Tandon V, Mukhtar R, Greninger A, Risi JD, Esserman LJ. Biology of breast cancer in Nigerian women: a pilot study. Ann Afr Med. 2012 Jul-Sep; 11(3):169-75. View in PubMed
  128. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012 Jun 10; 486(7403):353-60. View in PubMed
  129. Hylton NM, Blume JD, Bernreuter WK, Pisano ED, Rosen MA, Morris EA, Weatherall PT, Lehman CD, Newstead GM, Polin S, Marques HS, Esserman LJ, Schnall MD. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology. 2012 Jun; 263(3):663-72. View in PubMed
  130. Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M. A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. Lancet Oncol. 2012 Jun; 13(6):e240-8. View in PubMed
  131. Peled AW, Foster RD, Garwood ER, Moore DH, Ewing CA, Alvarado M, Hwang ES, Esserman LJ. The effects of acellular dermal matrix in expander-implant breast reconstruction after total skin-sparing mastectomy: results of a prospective practice improvement study. Plast Reconstr Surg. 2012 Jun; 129(6):901e-908e. View in PubMed
  132. Chang EI, Peled AW, Foster RD, Lin C, Zeidler KR, Ewing CA, Alvarado M, Hwang ES, Esserman LJ. Evaluating the feasibility of extended partial mastectomy and immediate reduction mammoplasty reconstruction as an alternative to mastectomy. Ann Surg. 2012 Jun; 255(6):1151-7. View in PubMed
  133. Esserman LJ, Berry DA, DeMichele A, Carey L, Davis SE, Buxton M, Hudis C, Gray JW, Perou C, Yau C, Livasy C, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, van 't Veer L, Hylton N. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol. 2012 Sep 10; 30(26):3242-9. View in PubMed
  134. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, Eleweke N, Au A, Baehner FL, Moore DH, McGrath MS, Olopade OI, Gray JW, Campbell MJ, Esserman LJ. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol. 2012 Nov; 19(12):3979-86. View in PubMed
  135. Esserman LJ. Breast cancer recurrence is dictated by high-risk biology, not choice of surgery. Oncology (Williston Park). 2012 May 15; 26(5). View in PubMed
  136. Warren Peled A, Foster RD, Stover AC, Itakura K, Ewing CA, Alvarado M, Hwang ES, Esserman LJ. Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts. Ann Surg Oncol. 2012 Oct; 19(11):3402-9. View in PubMed
  137. Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Creasman KJ, Bazarov AV, Smyth JW, Davis SE, Yaswen P, Mills GB, Esserman LJ, Goga A. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012 Apr 09; 209(4):679-96. View in PubMed
  138. Esserman L, Benz C, Demichele A. Targeting Molecular Aberrations in Breast Cancer: Is It about Time? Am Soc Clin Oncol Educ Book. 2012; 186-91. View in PubMed
  139. Alvarado M, Ozanne E, Esserman L. Overdiagnosis and overtreatment of breast cancer. Am Soc Clin Oncol Educ Book. 2012; e40-5. View in PubMed
  140. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, Chen YY, Giri D, Au A, Hylton N. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat. 2012 Apr; 132(3):1049-62. View in PubMed
  141. Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA. 2011 Dec 21; 306(23):2608-9. View in PubMed
  142. Loi S, Symmans WF, Bartlett JM, Fumagalli D, Van't Veer L, Forbes JF, Bedard P, Denkert C, Zujewski J, Viale G, Pusztai L, Esserman LJ, Leyland-Jones BR. Proposals for uniform collection of biospecimens from neoadjuvant breast cancer clinical trials: timing and specimen types. Lancet Oncol. 2011 Nov; 12(12):1162-8. View in PubMed
  143. Esserman LJ, Shieh Y, Rutgers EJ, Knauer M, Retèl VP, Mook S, Glas AM, Moore DH, Linn S, van Leeuwen FE, van 't Veer LJ. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. Breast Cancer Res Treat. 2011 Dec; 130(3):725-34. View in PubMed
  144. Meyerson AF, Lessing JN, Itakura K, Hylton NM, Wolverton DE, Joe BN, Esserman LJ, Hwang ES. Outcome of long term active surveillance for estrogen receptor-positive ductal carcinoma in situ. Breast. 2011 Dec; 20(6):529-33. View in PubMed
  145. Ruffell B, Au A, Rugo HS, Esserman LJ, Hwang ES, Coussens LM. Leukocyte composition of human breast cancer. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2796-801. View in PubMed
  146. Lin C, Buxton MB, Moore D, Krontiras H, Carey L, DeMichele A, Montgomery L, Tripathy D, Lehman C, Liu M, Olapade O, Yau C, Berry D, Esserman LJ. Locally advanced breast cancers are more likely to present as Interval Cancers: results from the I-SPY 1 TRIAL (CALGB 150007/150012, ACRIN 6657, InterSPORE Trial). Breast Cancer Res Treat. 2012 Apr; 132(3):871-9. View in PubMed
  147. Mukhtar RA, Moore AP, Nseyo O, Baehner FL, Au A, Moore DH, Twomey P, Campbell MJ, Esserman LJ. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity. Breast Cancer Res Treat. 2011 Nov; 130(2):635-44. View in PubMed
  148. Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):607-16. View in PubMed
  149. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81. View in PubMed
  150. Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011 Jun 10; 29(17):2342-9. View in PubMed
  151. Ozanne EM, Shieh Y, Barnes J, Bouzan C, Hwang ES, Esserman LJ. Characterizing the impact of 25 years of DCIS treatment. Breast Cancer Res Treat. 2011 Aug; 129(1):165-73. View in PubMed
  152. Itakura K, Lessing J, Sakata T, Heinzerling A, Vriens E, Wisner D, Alvarado M, Esserman L, Ewing C, Hylton N, Hwang ES. The impact of preoperative magnetic resonance imaging on surgical treatment and outcomes for ductal carcinoma in situ. Clin Breast Cancer. 2011 Mar; 11(1):33-8. View in PubMed
  153. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn. 2011 Jan; 11(1):91-100. View in PubMed
  154. Yau C, Esserman L, Moore DH, Waldman F, Sninsky J, Benz CC. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 2010; 12(5):R85. View in PubMed
  155. Hogarth M, Hajopoulos K, Young M, Cowles N, Churin J, Hornthal B, Esserman L. The Communication and Care Plan: a novel approach to patient-centered clinical information systems. J Biomed Inform. 2010 Oct; 43(5 Suppl):S6-8. View in PubMed
  156. Braithwaite D, Satariano WA, Sternfeld B, Hiatt RA, Ganz PA, Kerlikowske K, Moore DH, Slattery ML, Tammemagi M, Castillo A, Melisko M, Esserman L, Weltzien EK, Caan BJ. Long-term prognostic role of functional limitations among women with breast cancer. J Natl Cancer Inst. 2010 Oct 06; 102(19):1468-77. View in PubMed
  157. Campbell MJ, Tonlaar NY, Garwood ER, Huo D, Moore DH, Khramtsov AI, Au A, Baehner F, Chen Y, Malaka DO, Lin A, Adeyanju OO, Li S, Gong C, McGrath M, Olopade OI, Esserman LJ. Proliferating macrophages associated with high grade, hormone receptor negative breast cancer and poor clinical outcome. Breast Cancer Res Treat. 2011 Aug; 128(3):703-711. View in PubMed
  158. Liu LC, Lang JE, Lu Y, Roe D, Hwang SE, Ewing CA, Esserman LJ, Morita E, Treseler P, Leong SP. Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: a meta-analysis and single-institution experience. Cancer. 2011 Jan 15; 117(2):250-8. View in PubMed
  159. Esserman L, Kaklamani V. Lessons learned from genetic testing. JAMA. 2010 Sep 01; 304(9):1011-2. View in PubMed
  160. Warren Peled A, Itakura K, Foster RD, Hamolsky D, Tanaka J, Ewing C, Alvarado M, Esserman LJ, Hwang ES. Impact of chemotherapy on postoperative complications after mastectomy and immediate breast reconstruction. Arch Surg. 2010 Sep; 145(9):880-5. View in PubMed
  161. Belkora JK, Teng A, Volz S, Loth MK, Esserman LJ. Expanding the reach of decision and communication aids in a breast care center: a quality improvement study. Patient Educ Couns. 2011 May; 83(2):234-9. View in PubMed
  162. Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, Alvarado M, Flyger HL, Massarut S, Eiermann W, Keshtgar M, Dewar J, Kraus-Tiefenbacher U, Sütterlin M, Esserman L, Holtveg HM, Roncadin M, Pigorsch S, Metaxas M, Falzon M, Matthews A, Corica T, Williams NR, Baum M. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT-A trial): an international, prospective, randomised, non-inferiority phase 3 trial. Lancet. 2010 Jul 10; 376(9735):91-102. View in PubMed
  163. Chan LW, Rabban J, Hwang ES, Bevan A, Alvarado M, Ewing C, Esserman L, Fowble B. Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? Int J Radiat Oncol Biol Phys. 2011 May 01; 80(1):25-30. View in PubMed
  164. Esserman L, Thompson I. Solving the overdiagnosis dilemma. J Natl Cancer Inst. 2010 May 05; 102(9):582-3. View in PubMed
  165. Garwood ER, Kumar AS, Baehner FL, Moore DH, Au A, Hylton N, Flowers CI, Garber J, Lesnikoski BA, Hwang ES, Olopade O, Port ER, Campbell M, Esserman LJ. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010 Jan; 119(1):137-44. View in PubMed
  166. Zakhireh J, Fowble B, Esserman LJ. Application of screening principles to the reconstructed breast. J Clin Oncol. 2010 Jan 01; 28(1):173-80. View in PubMed
  167. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA. 2009 Oct 21; 302(15):1685-92. View in PubMed
  168. Mukhtar RA, Throckmorton AD, Alvarado MD, Ewing CA, Esserman LJ, Chiu C, Hwang ES. Bacteriologic features of surgical site infections following breast surgery. Am J Surg. 2009 Oct; 198(4):529-31. View in PubMed
  169. Chen YY, DeVries S, Anderson J, Lessing J, Swain R, Chin K, Shim V, Esserman LJ, Waldman FM, Hwang ES. Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ. BMC Cancer. 2009 Aug 18; 9:285. View in PubMed
  170. Lang JE, Magbanua MJ, Scott JH, Makrigiorgos GM, Wang G, Federman S, Esserman LJ, Park JW, Haqq CM. A comparison of RNA amplification techniques at sub-nanogram input concentration. BMC Genomics. 2009 Jul 20; 10:326. View in PubMed
  171. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther. 2009 Jul; 86(1):97-100. View in PubMed
  172. Olson JA, Budd GT, Carey LA, Harris LA, Esserman LJ, Fleming GF, Marcom PK, Leight GS, Giuntoli T, Commean P, Bae K, Luo J, Ellis MJ. Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg. 2009 May; 208(5):906-14; discussion 915-6. View in PubMed
  173. Lang JE, Liu LC, Lu Y, Jenkins T, Hwang SE, Esserman LJ, Ewing CA, Alvarado M, Morita E, Treseler P, Leong SP. Prognostic implications of positive nonsentinel lymph nodes removed during selective sentinel lymphadenectomy for breast cancer. Breast J. 2009 May-Jun; 15(3):242-6. View in PubMed
  174. Belkora JK, Rugo HS, Moore DH, Hutton DW, Chen DF, Esserman LJ. Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis. BMC Cancer. 2009 Apr 28; 9:127. View in PubMed
  175. Zhu J, Sanborn JZ, Benz S, Szeto C, Hsu F, Kuhn RM, Karolchik D, Archie J, Lenburg ME, Esserman LJ, Kent WJ, Haussler D, Wang T. The UCSC Cancer Genomics Browser. Nat Methods. 2009 Apr; 6(4):239-40. View in PubMed
  176. Braithwaite D, Tammemagi CM, Moore DH, Ozanne EM, Hiatt RA, Belkora J, West DW, Satariano WA, Liebman M, Esserman L. Hypertension is an independent predictor of survival disparity between African-American and white breast cancer patients. Int J Cancer. 2009 Mar 01; 124(5):1213-9. View in PubMed
  177. Garwood ER, Moore D, Ewing C, Hwang ES, Alvarado M, Foster RD, Esserman LJ. Total skin-sparing mastectomy: complications and local recurrence rates in 2 cohorts of patients. Ann Surg. 2009 Jan; 249(1):26-32. View in PubMed
  178. Throckmorton AD, Esserman LJ. When informed, all women do not prefer breast conservation. J Clin Oncol. 2009 Feb 01; 27(4):484-6. View in PubMed
  179. Ozanne EM, Braithwaite D, Sepucha K, Moore D, Esserman L, Belkora J. Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model. J Clin Oncol. 2009 Jan 10; 27(2):214-9. View in PubMed
  180. Tutt A, Wang A, Rowland C, Gillett C, Lau K, Chew K, Dai H, Kwok S, Ryder K, Shu H, Springall R, Cane P, McCallie B, Kam-Morgan L, Anderson S, Buerger H, Gray J, Bennington J, Esserman L, Hastie T, Broder S, Sninsky J, Brandt B, Waldman F. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer. 2008 Nov 21; 8:339. View in PubMed
  181. Zakhireh J, Gomez R, Esserman L. Converting evidence to practice: a guide for the clinical application of MRI for the screening and management of breast cancer. Eur J Cancer. 2008 Dec; 44(18):2742-52. View in PubMed
  182. Liu LC, Lang JE, Jenkins T, Lu Y, Ewing CA, Hwang SE, Sokol S, Alvarado M, Esserman LJ, Morita E, Treseler P, Leong SP. Is it necessary to harvest additional lymph nodes after resection of the most radioactive sentinel lymph node in breast cancer? J Am Coll Surg. 2008 Dec; 207(6):853-8. View in PubMed
  183. Belkora JK, Loth MK, Chen DF, Chen JY, Volz S, Esserman LJ. Monitoring the implementation of Consultation Planning, Recording, and Summarizing in a breast care center. Patient Educ Couns. 2008 Dec; 73(3):536-43. View in PubMed
  184. Belkora J, Rugo HS, Moore DH, Hutton D, Esserman L. Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. Lancet Oncol. 2008 Jul; 9(7):602-3. View in PubMed
  185. Li KL, Partridge SC, Joe BN, Gibbs JE, Lu Y, Esserman LJ, Hylton NM. Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging. Radiology. 2008 Jul; 248(1):79-87. View in PubMed
  186. Kumar AS, Benz CC, Shim V, Minami CA, Moore DH, Esserman LJ. Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users. Cancer Epidemiol Biomarkers Prev. 2008 May; 17(5):1028-33. View in PubMed
  187. Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, Miller MJ, Whelan T, Pierce LJ, Esserman LJ, Newman LA, Smith BL, Bear HD, Mamounas EP. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol. 2008 Feb 10; 26(5):791-7. View in PubMed
  188. Wulfkuhle JD, Speer R, Pierobon M, Laird J, Espina V, Deng J, Mammano E, Yang SX, Swain SM, Nitti D, Esserman LJ, Belluco C, Liotta LA, Petricoin EF. Multiplexed cell signaling analysis of human breast cancer applications for personalized therapy. J Proteome Res. 2008 Apr; 7(4):1508-17. View in PubMed
  189. Belkora J, Edlow B, Aviv C, Sepucha K, Esserman L. Training community resource center and clinic personnel to prompt patients in listing questions for doctors: follow-up interviews about barriers and facilitators to the implementation of consultation planning. Implement Sci. 2008 Jan 31; 3:6. View in PubMed
  190. Wijayanayagam A, Kumar AS, Foster RD, Esserman LJ. Optimizing the total skin-sparing mastectomy. Arch Surg. 2008 Jan; 143(1):38-45; discussion 45. View in PubMed
  191. Esserman LJ, Shieh Y, Park JW, Ozanne EM. A role for biomarkers in the screening and diagnosis of breast cancer in younger women. Expert Rev Mol Diagn. 2007 Sep; 7(5):533-44. View in PubMed
  192. Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol. 2007 Aug 20; 25(24):3680-7. View in PubMed
  193. Adduci KM, Annis CE, DeVries S, Chew KL, Boutin J, Magrane G, Ljung BM, Waldman FM, Esserman LJ. Fluorescence in situ hybridization of ductal lavage samples identifies malignant phenotypes from cytologically normal cells in women with breast cancer. Cancer. 2007 Jun 25; 111(3):185-91. View in PubMed
  194. Ozanne EM, Annis C, Adduci K, Showstack J, Esserman L. Pilot trial of a computerized decision aid for breast cancer prevention. Breast J. 2007 Mar-Apr; 13(2):147-54. View in PubMed
  195. Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL. Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol. 2007 Feb 20; 25(6):642-7. View in PubMed
  196. Wang Y, Moorhead M, Karlin-Neumann G, Wang NJ, Ireland J, Lin S, Chen C, Heiser LM, Chin K, Esserman L, Gray JW, Spellman PT, Faham M. Analysis of molecular inversion probe performance for allele copy number determination. Genome Biol. 2007; 8(11):R246. View in PubMed
  197. Chin K, DeVries S, Fridlyand J, Spellman PT, Roydasgupta R, Kuo WL, Lapuk A, Neve RM, Qian Z, Ryder T, Chen F, Feiler H, Tokuyasu T, Kingsley C, Dairkee S, Meng Z, Chew K, Pinkel D, Jain A, Ljung BM, Esserman L, Albertson DG, Waldman FM, Gray JW. Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. Cancer Cell. 2006 Dec; 10(6):529-41. View in PubMed
  198. Kumar AS, Cureton E, Shim V, Sakata T, Moore DH, Benz CC, Esserman LJ, Hwang ES. Type and duration of exogenous hormone use affects breast cancer histology. Ann Surg Oncol. 2007 Feb; 14(2):695-703. View in PubMed
  199. Esserman LJ, Kumar AS, Herrera AF, Leung J, Au A, Chen YY, Moore DH, Chen DF, Hellawell J, Wolverton D, Hwang ES, Hylton NM. Magnetic resonance imaging captures the biology of ductal carcinoma in situ. J Clin Oncol. 2006 Oct 01; 24(28):4603-10. View in PubMed
  200. Kumar AS, Chen DF, Au A, Chen YY, Leung J, Garwood ER, Gibbs J, Hylton N, Esserman LJ. Biologic significance of false-positive magnetic resonance imaging enhancement in the setting of ductal carcinoma in situ. Am J Surg. 2006 Oct; 192(4):520-4. View in PubMed
  201. Campbell MJ, Esserman LJ, Zhou Y, Shoemaker M, Lobo M, Borman E, Baehner F, Kumar AS, Adduci K, Marx C, Petricoin EF, Liotta LA, Winters M, Benz S, Benz CC. Breast cancer growth prevention by statins. Cancer Res. 2006 Sep 01; 66(17):8707-14. View in PubMed
  202. Belkora J, Katapodi M, Moore D, Franklin L, Hopper K, Esserman L. Evaluation of a visit preparation intervention implemented in two rural, underserved counties of Northern California. Patient Educ Couns. 2006 Dec; 64(1-3):350-9. View in PubMed
  203. Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM. Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice. Cancer Gene Ther. 2006 Nov; 13(11):1002-10. View in PubMed
  204. Kumar AS, Benz CC, Esserman LJ. Clinical trials are required to prove the chemopreventive worth of statins. Arch Intern Med. 2006 May 22; 166(10):1143; author reply 1144. View in PubMed
  205. Kumar AS, Campbell M, Benz CC, Esserman LJ. A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes. J Clin Oncol. 2006 May 01; 24(13):2127; author reply 2127-8. View in PubMed
  206. Esserman L, Sexton R, Yu QQ, Cabello-Inchausti B. Mammographic, sonographic, and pathologic characteristics of Burkitt's lymphoma in a patient referred for diagnostic mammography. AJR Am J Roentgenol. 2006 Apr; 186(4):1029-32. View in PubMed
  207. Ozanne EM, Klemp JR, Esserman LJ. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J. 2006 Mar-Apr; 12(2):103-13. View in PubMed
  208. Daly MB, Axilbund JE, Bryant E, Buys S, Eng C, Friedman S, Esserman LJ, Farrell CD, Ford JM, Garber JE, Jeter JM, Kohlmann W, Lynch PM, Marcom PK, Nabell LM, Offit K, Osarogiagbon RU, Pasche B, Reiser G, Sutphen R, Weitzel JN. Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw. 2006 Feb; 4(2):156-76. View in PubMed
  209. Kumar AS, Esserman LJ. Statins: health-promoting agents show promise for breast cancer prevention. Clin Breast Cancer. 2005 Dec; 6(5):455-9. View in PubMed
  210. Esserman LJ, Ozanne EM, Dowsett M, Slingerland JM. Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis. Breast Cancer Res. 2005; 7(6):R1153-8. View in PubMed
  211. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA. 2005 Oct 19; 294(15):1925-33. View in PubMed
  212. Tan YY, Wu CT, Fan YG, Hwang S, Ewing C, Lane K, Esserman L, Lu Y, Treseler P, Morita E, Leong SP. Primary tumor characteristics predict sentinel lymph node macrometastasis in breast cancer. Breast J. 2005 Sep-Oct; 11(5):338-43. View in PubMed
  213. Fan YG, Tan YY, Wu CT, Treseler P, Lu Y, Chan CW, Hwang S, Ewing C, Esserman L, Morita E, Leong SP. The effect of sentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer. Ann Surg Oncol. 2005 Sep; 12(9):705-11. View in PubMed
  214. Tan YY, Fan YG, Lu Y, Hwang S, Ewing C, Esserman L, Morita E, Treseler P, Leong SP. Ratio of positive to total number of sentinel nodes predicts nonsentinel node status in breast cancer patients. Breast J. 2005 Jul-Aug; 11(4):248-53. View in PubMed
  215. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol. 2005 Jun; 184(6):1774-81. View in PubMed
  216. Petricoin EF, Bichsel VE, Calvert VS, Espina V, Winters M, Young L, Belluco C, Trock BJ, Lippman M, Fishman DA, Sgroi DC, Munson PJ, Esserman LJ, Liotta LA. Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol. 2005 May 20; 23(15):3614-21. View in PubMed
  217. Campbell MJ, Scott J, Maecker HT, Park JW, Esserman LJ. Immune dysfunction and micrometastases in women with breast cancer. Breast Cancer Res Treat. 2005 May; 91(2):163-71. View in PubMed
  218. Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol. 2005 Mar 10; 23(8):1601-2. View in PubMed
  219. Misell LM, Hwang ES, Au A, Esserman L, Hellerstein MK. Development of a novel method for measuring in vivo breast epithelial cell proliferation in humans. Breast Cancer Res Treat. 2005 Feb; 89(3):257-64. View in PubMed
  220. Foster RD, Hansen SL, Esserman LJ, Hwang ES, Ewing C, Lane K, Anthony JP. Safety of immediate transverse rectus abdominis myocutaneous breast reconstruction for patients with locally advanced disease. Arch Surg. 2005 Feb; 140(2):196-8; discussion 199-200. View in PubMed
  221. Park C, Seid P, Morita E, Iwanaga K, Weinberg V, Quivey J, Hwang ES, Esserman LJ, Leong SP. Internal mammary sentinel lymph node mapping for invasive breast cancer: implications for staging and treatment. Breast J. 2005 Jan-Feb; 11(1):29-33. View in PubMed
  222. Lee R, Beattie M, Crawford B, Mak J, Stewart N, Komaromy M, Esserman L, Shaw L, McLennan J, Strachowski L, Luce J, Ziegler J. Recruitment, genetic counseling, and BRCA testing for underserved women at a public hospital. Genet Test. 2005; 9(4):306-12. View in PubMed
  223. Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, Hwang ES. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004 Dec; 199(6):856-62. View in PubMed
  224. Ozanne EM, Esserman LJ. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis. Cancer Epidemiol Biomarkers Prev. 2004 Dec; 13(12):2043-52. View in PubMed
  225. Hwang ES, Nyante SJ, Yi Chen Y, Moore D, DeVries S, Korkola JE, Esserman LJ, Waldman FM. Clonality of lobular carcinoma in situ and synchronous invasive lobular carcinoma. Cancer. 2004 Jun 15; 100(12):2562-72. View in PubMed
  226. Esserman L, Sepucha K, Ozanne E, Hwang ES. Applying the neoadjuvant paradigm to ductal carcinoma in situ. Ann Surg Oncol. 2004 Jan; 11(1 Suppl):28S-36S. View in PubMed
  227. Hwang ES, Esserman L. Neoadjuvant hormonal therapy for ductal carcinoma in situ: trial design and preliminary results. Ann Surg Oncol. 2004 Jan; 11(1 Suppl):37S-43S. View in PubMed
  228. Esserman L. Neoadjuvant chemotherapy for primary breast cancer: lessons learned and opportunities to optimize therapy. Ann Surg Oncol. 2004 Jan; 11(1 Suppl):3S-8S. View in PubMed
  229. Tjandra D, Wong S, Shen W, Pulliam B, Yu E, Esserman L. An XML message broker framework for exchange and integration of microarray data. Bioinformatics. 2003 Sep 22; 19(14):1844-5. View in PubMed
  230. del Carmen MG, Hughes KS, Halpern E, Rafferty E, Kopans D, Parisky YR, Sardi A, Esserman L, Rust S, Michaelson J. Racial differences in mammographic breast density. Cancer. 2003 Aug 01; 98(3):590-6. View in PubMed
  231. Shim V, Gauthier ML, Sudilovsky D, Mantei K, Chew KL, Moore DH, Cha I, Tlsty TD, Esserman LJ. Cyclooxygenase-2 expression is related to nuclear grade in ductal carcinoma in situ and is increased in its normal adjacent epithelium. Cancer Res. 2003 May 15; 63(10):2347-50. View in PubMed
  232. Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. Ann Surg Oncol. 2003 May; 10(4):381-8. View in PubMed
  233. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM. MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators? Int Immunol. 2003 Apr; 15(4):467-75. View in PubMed
  234. Wu CT, Morita ET, Treseler PA, Esserman LJ, Hwang ES, Kuerer HM, Santos CL, Leong SP. Failure to harvest sentinel lymph nodes identified by preoperative lymphoscintigraphy in breast cancer patients. Breast J. 2003 Mar-Apr; 9(2):86-90. View in PubMed
  235. Sepucha KR, Belkora JK, Aviv C, Mutchnik S, Esserman LJ. Improving the quality of decision making in breast cancer: consultation planning template and consultation recording template. Oncol Nurs Forum. 2003 Jan-Feb; 30(1):99-106. View in PubMed
  236. Parisky YR, Sardi A, Hamm R, Hughes K, Esserman L, Rust S, Callahan K. Efficacy of computerized infrared imaging analysis to evaluate mammographically suspicious lesions. AJR Am J Roentgenol. 2003 Jan; 180(1):263-9. View in PubMed
  237. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol. 2002 Nov; 179(5):1193-9. View in PubMed
  238. Cura MA, Blanco M, Esserman L. Axillary metastasis from a malignant mullerian mixed tumor. Breast J. 2002 Sep-Oct; 8(5):305-6. View in PubMed
  239. Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman LJ, Peterlin BM. Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers. Mol Cell Biol. 2002 Aug; 22(15):5616-25. View in PubMed
  240. Euhus DM, Smith KC, Robinson L, Stucky A, Olopade OI, Cummings S, Garber JE, Chittenden A, Mills GB, Rieger P, Esserman L, Crawford B, Hughes KS, Roche CA, Ganz PA, Seldon J, Fabian CJ, Klemp J, Tomlinson G. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst. 2002 Jun 05; 94(11):844-51. View in PubMed
  241. Sepucha KR, Belkora JK, Mutchnick S, Esserman LJ. Consultation planning to help breast cancer patients prepare for medical consultations: effect on communication and satisfaction for patients and physicians. J Clin Oncol. 2002 Jun 01; 20(11):2695-700. View in PubMed
  242. Esserman L, Wolverton D, Hylton N. Magnetic resonance imaging for primary breast cancer management: current role and new applications. Endocr Relat Cancer. 2002 Jun; 9(2):141-53. View in PubMed
  243. Foster RD, Esserman LJ, Anthony JP, Hwang ES, Do H. Skin-sparing mastectomy and immediate breast reconstruction: a prospective cohort study for the treatment of advanced stages of breast carcinoma. Ann Surg Oncol. 2002 Jun; 9(5):462-6. View in PubMed
  244. Campbell MJ, Wollish WS, Lobo M, Esserman LJ. Epithelial and fibroblast cell lines derived from a spontaneous mammary carcinoma in a MMTV/neu transgenic mouse. In Vitro Cell Dev Biol Anim. 2002 Jun; 38(6):326-33. View in PubMed
  245. Esserman LJ. New approaches to the imaging, diagnosis, and biopsy of breast lesions. Cancer J. 2002 May-Jun; 8 Suppl 1:S1-14. View in PubMed
  246. Esserman L, Cowley H, Eberle C, Kirkpatrick A, Chang S, Berbaum K, Gale A. Improving the accuracy of mammography: volume and outcome relationships. J Natl Cancer Inst. 2002 Mar 06; 94(5):369-75. View in PubMed
  247. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, Kuerer HM, Hung DT, Khan SA, Phillips RF, Ganz PA, Euhus DM, Esserman LJ, Haffty BG, King BL, Kelley MC, Anderson MM, Schmit PJ, Clark RR, Kass FC, Anderson BO, Troyan SL, Arias RD, Quiring JN, Love SM, Page DL, King EB. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001 Nov 07; 93(21):1624-32. View in PubMed
  248. Haas J, Kaplan C, McMillan A, Esserman LJ. Does timely assessment affect the anxiety associated with an abnormal mammogram result? J Womens Health Gend Based Med. 2001 Jul-Aug; 10(6):599-605. View in PubMed
  249. Burnside E, Belkora J, Esserman L. The impact of alternative practices on the cost and quality of mammographic screening in the United States. Clin Breast Cancer. 2001 Jul; 2(2):145-52. View in PubMed
  250. Esserman L, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, Hwang S, Kuerer H, Sudilovsky D, Lu Y, Hylton N. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer. Ann Surg Oncol. 2001 Jul; 8(6):549-59. View in PubMed
  251. Mukherjee S, Louie SG, Campbell M, Esserman L, Shyamala G. Ductal growth is impeded in mammary glands of C-neu transgenic mice. Oncogene. 2000 Dec 07; 19(52):5982-7. View in PubMed
  252. Frei KA, Kinkel K, Bonel HM, Lu Y, Esserman LJ, Hylton NM. MR imaging of the breast in patients with positive margins after lumpectomy: influence of the time interval between lumpectomy and MR imaging. AJR Am J Roentgenol. 2000 Dec; 175(6):1577-84. View in PubMed
  253. Esserman LJ, Wolverton D, Hylton N. Integration of breast imaging into cancer management. Curr Oncol Rep. 2000 Nov; 2(6):572-81. View in PubMed
  254. Kinkel K, Helbich TH, Esserman LJ, Barclay J, Schwerin EH, Sickles EA, Hylton NM. Dynamic high-spatial-resolution MR imaging of suspicious breast lesions: diagnostic criteria and interobserver variability. AJR Am J Roentgenol. 2000 Jul; 175(1):35-43. View in PubMed
  255. Kuerer HM, Hwang ES, Anthony JP, Dudley RA, Crawford B, Aubry WM, Esserman LJ. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery. Ann Surg Oncol. 2000 Jun; 7(5):325-32. View in PubMed
  256. Sepucha KR, Belkora JK, Tripathy D, Esserman LJ. Building bridges between physicians and patients: results of a pilot study examining new tools for collaborative decision making in breast cancer. J Clin Oncol. 2000 Mar; 18(6):1230-8. View in PubMed
  257. Hwang ES, Esserman LJ. Management of ductal carcinoma in situ. Surg Clin North Am. 1999 Oct; 79(5):1007-30, viii. View in PubMed
  258. Borden EC, Esserman L, Linder DJ, Campbell MJ, Fulton AM. Biological therapies for breast carcinoma: concepts for improvement in survival. Semin Oncol. 1999 Aug; 26(4 Suppl 12):28-40. View in PubMed
  259. Kuerer HM, Hwang ES, Esserman LJ. Prophylactic mastectomy in women with a high risk of breast cancer. N Engl J Med. 1999 Jun 10; 340(23):1838; author reply 1839. View in PubMed
  260. Esserman LJ, Lopez T, Montes R, Bald LN, Fendly BM, Campbell MJ. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol Immunother. 1999 Feb; 47(6):337-42. View in PubMed
  261. Esserman L, Hylton N, George T, Weidner N. Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma. Breast J. 1999 Jan; 5(1):13-21. View in PubMed
  262. Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol. 1999 Jan; 17(1):110-9. View in PubMed
  263. Ballagh SA, Stover TL, Maragos TG, Reynolds MD, Wolfley GD, Esserman LJ, Herbst JR, Kirkegaard LW, Teichman SL. A multicenter randomized trial of DIAC for cyclical mastopathy. Prim Care Update Ob Gyns. 1998 Jul 01; 5(4):211. View in PubMed
  264. Esserman L, Weidner N. Is routine frozen section assessment feasible in the practice environment of the 1990s? Cancer J Sci Am. 1997 Sep-Oct; 3(5):266-7. View in PubMed
  265. Burke CC, Gullatte MM, Vigliani M, Ruggiero RJ, Esserman L, Crawford B. Hormone replacement therapy and breast cancer risk. Cancer Pract. 1997 Jul-Aug; 5(4):203-8. View in PubMed
  266. Mortensen CL, Edmonds PD, Gorfu Y, Hill JR, Jensen JF, Schattner P, Shifrin LA, Valdes AD, Jeffrey SS, Esserman LJ. Ultrasound tissue characterization of breast biopsy specimens: expanded study. Ultrason Imaging. 1996 Jul; 18(3):215-30. View in PubMed
  267. Igoe S, Collins C, Hamolsky D, Esserman LJ. Barriers to care and treatment: the challenge of daily radiation therapy. Cancer Pract. 1996 Mar-Apr; 4(2):65-7. View in PubMed
  268. Esserman L, Kerlikowske K. Should we recommend screening mammography for women aged 40 to 49? Oncology (Williston Park). 1996 Mar; 10(3):357-64; discussion: 370-6. View in PubMed
  269. Hillner BE, Desch CE, Carlson RW, Smith TJ, Esserman L, Bear HD. Trade-offs between survival and breast preservation for three initial treatments of ductal carcinoma-in-situ of the breast. J Clin Oncol. 1996 Jan; 14(1):70-7. View in PubMed
  270. Weidner N, Esserman LJ. Breast. Pathology (Phila). 1996; 3(2):417-26. View in PubMed
  271. Esserman L, Belkora J, Lenert L. Potentially ineffective care. A new outcome to assess the limits of critical care. JAMA. 1995 Nov 15; 274(19):1544-51. View in PubMed
  272. Metkus AP, Esserman L, Sola A, Harrison MR, Adzick NS. Cost per anomaly: what does a diaphragmatic hernia cost? J Pediatr Surg. 1995 Feb; 30(2):226-30. View in PubMed
  273. Takahashi S, Esserman L, Levy R. An epitope on the transferrin receptor preferentially exposed during tumor progression in human lymphoma is close to the ligand binding site. Blood. 1991 Feb 15; 77(4):826-32. View in PubMed
  274. Zelenetz AD, Campbell MJ, Bahler DW, Takahashi S, Oren R, Esserman L, Umetsu DT, Kwak LW, Maloney DG, Brown S. Follicular lymphoma: a model of lymphoid tumor progression in man. Ann Oncol. 1991 Feb; 2 Suppl 2:115-22. View in PubMed
  275. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J Immunol. 1990 Aug 01; 145(3):1029-36. View in PubMed
  276. Campbell MJ, Esserman L, Byars NE, Allison AC, Levy R. Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int Rev Immunol. 1989; 4(4):251-70. View in PubMed
  277. Campbell MJ, Esserman L, Levy R. Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J Immunol. 1988 Nov 01; 141(9):3227-33. View in PubMed
  278. Ginsburg R, Esserman LJ, Bristow MR. Myocardial performance and extracellular ionized calcium in a severely failing human heart. Ann Intern Med. 1983 May; 98(5 Pt 1):603-6. View in PubMed
  279. Goldman MP, Esserman LJ, Bausback KN, Camargo CA, Nagel DA. A novel method for emergency immobilization of the wrist during cross-country skiing. Am J Sports Med. 1980 Jul-Aug; 8(4):285-6. View in PubMed
Data provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Laura J. Esserman, M.D., M.B.A.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.